来源：中国新闻网 中新网上海6月23日电(记者 宋宇晟)"通向AGI(通用人工智能)之路要经历多个阶段，目前(AI技术)正处 于从'思考'向'行动'跨越阶段。" 在近日举行的2025上海世界移动通信大会(MWC上海)期间，荣耀CEO李健给出了这样的判断。他认 为，AGI将是一个长期演进的过程，当务之急是要"让AI能解决问题"，只有让AI落地生根，让用户日常 使用起来，才能真正释放AI的潜力。 在GSMA(全球移动通信系统协会)会长白德伟(Vivek Badrinath)看来，中国是全球最大的5G市场，并在 AI与开放式API的发展方面走在前沿，这一切得益于运营商与开发者之间的深度协作。 GSMA Ltd.首席执行官洪曜庄(John Hoffman)表示，展会现场所呈现的创新成果充分彰显了亚洲数字与 移动产业的惊人变革速度。 AI是一场前所未有的科技革命，将深刻重构产业格局。 "AI正在以惊人的速度临近奇点，技术爆发式增长的前夜已经到来。"李健指出，从局部应用到系统重构 的技术革命，从单体智能到集群智慧的产业进化，从效率提升到价值重塑的商业的跃迁，AI正在改变 人们的生产生活方式，成为推动社会经济人文变革的动力 ...

证券代码：835184 证券简称：国源科技 公告编号：2025-066 √特定对象调研 二、投资者关系活动情况 活动时间：2025 年 6 月 19 日 活动地点：北京世纪国源科技股份有限公司会议室 参会单位及人员：北京神农投资管理股份有限公司 孙一明、齐飞翔 上市公司接待人员：董事会秘书 尚红英 三、投资者关系活动主要内容 本次投资者关系活动的主要问题及公司对问题的回复概要如下： 问题 1：可否结合公司主营业务介绍公司所处细分行业的情况以及与之对应 的同行业可比公司都有哪些？ 北京世纪国源科技股份有限公司 投资者关系活动记录表 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、投资者关系活动类别 回复：目前公司主营业务仍以政府客户为基本盘，积极拓展多元客户体系， 目前已拓展了农业保险公司、涉农银行、社会化服务组织等企业级客户。相对上 市前，公司企业客户收入已有大幅提升。以农业保险为例，公司围绕农业保险公 司"精准承保、精准理赔"的需求痛点，公司推出农业保险数字地图+地图服务 引擎+地图应用工具+技术 ...

Group 1 - The article promotes a portfolio strategy that generates income without the need for selling assets, aiming to simplify retirement investing [1][2] - It emphasizes community and education, suggesting that investors should not navigate the investment landscape alone [2] - The service offers features such as model portfolios, buy/sell alerts, and regular market updates to support investors [2][4] Group 2 - The article mentions the involvement of contributors who provide insights and recommendations, indicating a collaborative approach to investment strategies [4] - It highlights the importance of monitoring positions and issuing alerts to members, ensuring active management of investments [4]

Core Viewpoint - Aero Energy Limited has successfully completed the acquisition of Kraken Energy Corp, creating a leading North American uranium developer by combining their respective assets and strengths [1][2]. Company Overview - The merger combines Aero's 250,000-acre land package in Saskatchewan's Athabasca Basin with Kraken's high-grade uranium properties in the U.S., including the Apex Uranium Property, Nevada's largest past-producing uranium mine [12]. - The new entity aims to unlock high-grade, unconformity-style mineralization and capitalize on the growing demand for uranium [12]. Transaction Details - Under the terms of the arrangement, all issued and outstanding Kraken Shares were exchanged for a total of 57,922,329 common shares of Aero at an exchange ratio of 0.97037 Aero Shares for each Kraken Share [3]. - Following the completion of the arrangement, Aero has 179,849,606 shares issued and outstanding, with approximately 67.79% held by Aero's shareholders prior to the arrangement and 32.21% by former Kraken shareholders [3]. Leadership Changes - The board of directors of Aero post-merger consists of five members, including three existing Aero directors and two nominees from Kraken [5]. - Galen McNamara continues as CEO and Director of Aero, with Carson Halliday appointed as CFO and Corporate Secretary [5]. Regulatory Approvals - The Supreme Court of British Columbia approved the arrangement on June 17, 2025, and the shareholders of Kraken approved the transaction at their annual general and special meeting on June 11, 2025 [2][3]. Market Impact - The merger is expected to enhance the companies' ability to unlock permits and scale operations effectively, positioning them to capture momentum in the uranium market [2]. - The Kraken Shares are anticipated to be de-listed from the Canadian Securities Exchange effective June 20, 2025, and Aero plans to terminate Kraken's public reporting obligations [8].

Core Insights - Fractyl Health's Rejuva platform shows promise as a one-time, durable therapy for obesity and type 2 diabetes (T2D), demonstrating a favorable toxicity profile in preclinical studies [1][2][4] - The mechanism of action for Rejuva is distinct from systemic GLP-1 receptor agonists, allowing for nutrient-responsive secretion that activates only under metabolic stress [2][3] - Preliminary clinical data for RJVA-001, the first clinical candidate from the Rejuva platform, is expected in 2026, pending regulatory authorization [5][11] Key Findings - A single dose of Rejuva in a study with mice resulted in a 20% reduction in body weight and a 38% decrease in blood glucose levels by day 21, effects maintained despite continued high-fat diet exposure [7] - Rejuva-treated lean animals showed no weight gain or hyperglycemia when switched to a high-fat diet, maintaining baseline body weight and showing an 8% reduction in blood glucose [7] - The treatment was well-tolerated with no signs of toxicity or excessive weight loss in healthy animals, reinforcing the self-limiting nature of Rejuva's mechanism [7] Momentum Toward the Clinic - Fractyl Health has completed key in vivo studies for RJVA-001 and anticipates dosing the first patients in 2026, aiming for a first-in-class gene therapy that reprograms the pancreas for natural metabolic control [5][11] Scientific Validation - The study was conducted by a team from Fractyl Health and the University of Michigan, including experts in metabolic diseases, highlighting the scientific momentum behind Rejuva's approach [6][8]

Core Viewpoint - NFI Group Inc. is expanding its partnership with Brampton Transit by delivering 55 new Xcelsior buses, which includes both hybrid-electric and clean-diesel models, to enhance the city's transit fleet and support sustainable mobility solutions [2][3]. Group 1: Company Overview - NFI Group Inc. is a leader in propulsion-agnostic bus and coach mobility solutions, with a broad product portfolio that includes electric and hybrid models [5][8]. - The company has a significant presence in the bus manufacturing industry, employing nearly 9,000 team members across ten countries and supporting over 100,000 buses and coaches globally [6][7]. Group 2: Recent Developments - The new order for Brampton Transit consists of 20 hybrid-electric 40-foot buses and 35 clean-diesel 60-foot buses, totaling 70 equivalent units, which will be added to New Flyer's second quarter 2025 backlog [2]. - This order marks a continuation of a long-term relationship, with over 300 buses delivered to Brampton over the past 30 years, highlighting the company's commitment to innovative mobility solutions [3]. Group 3: Product Benefits - New Flyer's Xcelsior buses are designed to provide improved fuel efficiency, reduced emissions, and strong operational reliability, making them suitable for modern transit needs [4]. - The buses utilize advanced engines and ultra-low sulfur diesel, contributing to sustainable transportation solutions that support community growth [4].

– NOT FOR DISSEMINATION IN THE UNITED STATES OR THROUGH U.S. NEWSWIRE SERVICES –Vancouver, BC, June 23, 2025 (GLOBE NEWSWIRE) -- New Wave Holdings Corp., to be renamed Humanoid Global Holdings Corp., (“New Wave” or the “Company”) (CSE:NWAI, FWB:0XM0, OTCPK:TRMNF) is pleased to announce that it will proceed with a non-brokered private placement of up to 10,000,000 units of the Company (the “Units”) at $0.30 per Unit for gross proceeds of up to $3,000,000 (the “Offering”).Each Unit will consist of one common ...

Enrollment of 51 subjects highlights significant unmet need in this serious, lifelong genetic disease which currently has no FDA-approved therapies Top-line data expected in the first quarter of 2026 WAYNE, Pa., June 23, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: PVLA) Palvella Therapeutics, Inc. (Palvella), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no U.S. Food and Drug ...

SHANGHAI and HONG KONG, June 23, 2025 (GLOBE NEWSWIRE) -- NETCLASS Technology INC (Nasdaq: NTCL; the “Company” or “NetClass”), a leading B2B smart education IT solutions provider with offices in Shanghai, Hong Kong, Singapore and Tokyo, is pleased to announce that it signed a Framework Agreement for Cooperation with Nanyang Institute of Social Sciences Ptd. Ltd. (“Nanyang Institute of Social Sciences”), a private higher education institution registered with Singapore’s Ministry of Education, to mark the beg ...

Proposed reverse merger with OrthoCellix, a wholly-owned subsidiary of Ocugen, to create Nasdaq-listed, late clinical-stage regenerative cell therapy company with a first-in-class technology platform, focused on orthopedic diseasesOrthoCellix is developing the Phase 3-ready NeoCart® as an autologous cartilage implant technology utilizing patient cells to repair articular cartilage defects of the knee PHILADELPHIA and MALVERN, Pa., June 23, 2025 (GLOBE NEWSWIRE) -- Carisma Therapeutics Inc. (Nasdaq: CARM) (C ...